Skip to main content
. 2021 Nov 11;11:762444. doi: 10.3389/fonc.2021.762444

Table 4.

Selected adjuvant and neoadjuvant treatment characteristics according to myosteatosis of stage I–III colon and rectal cancer patients, respectively.

Characteristic Colon cancer patients that underwent adjuvant treatment
No myosteatosis, n = 31 Myosteatosis, n = 63 p value
Chemotherapy regimen
5-FU plus oxaliplatin 23 (82.1) 36 (57.1) 0.031
5-FU plus leucovorin 5 (17.9) 27 (42.9)
Adjuvant treatment complete, № (%) 25 (80.7) 35 (55.6) 0.022 a
Adjuvant treatment interrupted, № (%)
Toxicity 1 (3.2) 17 (27.0) 0.005 a
Performance deterioration 1 (3.3) 2 (3.2) 1.000 a
Progression 1 (3.2) 4 (6.4) 1.000 a
Abandonment 2 (6.3) 4 (6.4) 1.000 a
NR 1 (3.2) 1 (1.6) 1.000 a
Toxicity grades III–IV, № (%)
All 12 (26.1) 19 (39.6) 0.164 a
Diarrhea 6 (19.4) 18 (28.6) 0.452 a
Emesis 2 (6.5) 0 (0.0) 0.116 a
Mucositis 3 (9.7) 2 (3.2) 0.327 a
Hematological 1 (3.2) 11 (17.5) 0.096 a
Characteristic Rectal cancer patients that underwent neoadjuvant treatment
No myosteatosis, n = 36 Myosteatosis, n = 50 p value
5-FU or capecitabine plus radiotherapy, № (%) 36 (100.0) 50 (100.0) 1.00
Neoadjuvant treatment complete, № (%) 31 (86.1) 48 (96.0) 0.124 b
Neoadjuvant treatment interrupted 5 (13.9) 2 (4.0)
Toxicity grades III–IV, № (%)
All 10 (27.8) 16 (32.0) 0.674 a
Diarrhea 6 (16.7) 12 (24.0) 0.592 a
Emesis 2 (5.6) 1 (2.0) 0.569 a
Mucositis 0 (0.0) 2 (4.0) 0.508 a
Hematological 2 (5.6) 0 (0.0) 0.172 a

NR, not reported

a

Fisher’s exact test.

b

Chi-square test.